News
NTRB
3.650
-5.19%
-0.200
Nutriband signs exclusive supplier agreement with Fit for Life
Nutriband signs exclusive supplier agreement with Fit for Life. Nutriband's wholly owned contract manufacturing unit, Active Intelligence, will act as manufacturer for FFL's new product launch under one of their top brands. The company is a subsidiary of Fit For Life Inc.
Seeking Alpha · 2d ago
Weekly Report: what happened at NTRB last week (0415-0419)?
Weekly Report · 3d ago
Nutriband Discloses $8.4M Private Placement Representing 2.10M Shares Of Common Stock At $4 Per Share; Company Targets 505(b)(2) NDA To FDA For Marketing Approval Of AVERSA Fentanyl In Q1 2025
AVERSA Fentanyl has the potential to become the world's first opioid patch with abuse deterrent properties. The private placement is expected to close in 2024. The company says it could reach peak annual US sales of $80 million to $200 million. Company says each investor receives a five-year warrant to purchase two shares of stock.
Benzinga · 6d ago
Weekly Report: what happened at NTRB last week (0408-0412)?
Weekly Report · 04/15 12:01
Weekly Report: what happened at NTRB last week (0401-0405)?
Weekly Report · 04/08 12:08
Nutriband stock climbs on receiving first order for sports brand licensee Fit for Life Group
Nutriband stock climbs on receiving first order for sports brand licensee Fit for Life Group. Nutriband shares rise about 12% in early trading after announcing first order from Fit For Life Group, a major brand license holder. The company's shares are up about 12%.
Seeking Alpha · 04/01 14:18
Precision Biosciences, Mesoblast, Pulse Biosciences among healthcare movers
Precision Biosciences, Mesoblast, Pulse Bioscience among healthcare movers. S&P 500 Health Care Sector -0.89% to 1708.7. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index. Health Care Select Sector SPDR® Fund ETF.
Seeking Alpha · 04/01 14:00
Weekly Report: what happened at NTRB last week (0325-0329)?
Weekly Report · 04/01 12:04
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. The company reported a wider-than-expected fourth-quarter loss. Avalo Therapeutics, Inc. Shares jumped 430% in today's mid-day session. Other stocks moving in the market include RH, Ggoorks and Xilio.
Benzinga · 03/28 18:08
KOD, ALLG and SST among mid-day movers
On the Move KOD, ALLG and SST among mid-day movers. Avalo Therapeutics, UGRO, VEEE, CERO, GCTS, allG and VEEE are among the biggest gainers. Kodiak Sciences, Vee and Nutriband are the biggest losers.
Seeking Alpha · 03/28 17:01
Nutriband Shares Rise 30% After Fentanyl Patch Partnership News, Planned FDA Submission
Nutriband says it partnered with Kindeva Drug Delivery to develop a transdermal fentanyl patch system. Nutriband shares were trading 30% higher, at $3.96 each, in Wednesday's market. The company said the partnership will incorporate its technology into Kindeva's FDA-approved system.
Dow Jones · 03/27 19:17
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
LuxUrban Hotels shares dipped 27.4% to $1.5523 on Wednesday. The company issued preliminary fourth-quarter revenue outlook below estimates. MariaDB plc shares climbed 70.4%. Lixte Biotechnology Holdings, Inc. Shares jumped 68.6% in mid-day session.
Benzinga · 03/27 17:06
12 Health Care Stocks Moving In Wednesday's Intraday Session
Stoke Therapeutics (NASDAQ:STOK) shares increased by 46.1% to $15.03 during Wednesday's regular session. The company's market cap stands at $671.1 million. Nutriband stock rose 24.33% as the company's Q4 earnings came out yesterday. Lixte Biotechnology and Ontrak also moved upwards.
Benzinga · 03/27 16:31
iBio, ImmunityBio, Mesoblast among healthcare movers
IBio, ImmunityBio, Mesoblast among healthcare movers. S&P 500 Health Care Sector +1.04% to 1717.5. Pharmaceuticals, Biotechnology & Life Science contributes 58% to the index. IBio, immunityBio, mesoblast are among the biggest gainers.
Seeking Alpha · 03/27 14:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Lixte Biotechnology (NASDAQ:LIXT) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The company's, Q4 earnings came out today. NovoCure stock rose 17.9% and Nutriband shares rose 24.34% in the same session. Akili stock decreased by 20.6% and OpGen stock fell 15.67% during the session.
Benzinga · 03/27 13:05
Nutriband Provided An Overview Of The Clinical Development And Regulatory Pathway For Its Lead Product, Aversa Fentanyl, An Abuse-deterrent Fentanyl Transdermal Patch
AVERSA Fentanyl incorporates Nutriband's Aversa abuse-deterrent technology with an FDA-approved fentanyl patch. The drug is being developed via a limited 505(b)(2) New Drug Application pathway. NDA will be based on a single Phase 1 human abuse potential clinical study.
Benzinga · 03/27 09:57
Weekly Report: what happened at NTRB last week (0318-0322)?
Weekly Report · 03/25 12:08
12 Health Care Stocks Moving In Friday's After-Market Session
Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The company's market cap stands at $8.0 billion. Masimo shares rose 12.48% and NextCure shares declined by 9.5% during the same session.
Benzinga · 03/22 21:33
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Biolase (NASDAQ:BIOL) shares moved upwards by 61.5% to $0.24 during Friday's pre-market session. Eton Pharmaceuticals shares rose 15.46% during the day. Outlook Therapeutics and Nutriband also moved upwards. SINTX Techs shares declined by 34.0% in the pre- market.
Benzinga · 03/22 13:06
Weekly Report: what happened at NTRB last week (0311-0315)?
Weekly Report · 03/18 12:06
More
Webull provides a variety of real-time NTRB stock news. You can receive the latest news about Nutriband Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTRB
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. The Company's development pipeline includes AVERSA Buprenorphine and AVERSA Methylphenidate. The Company is also developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. Its AVERSA Fentanyl is an abuse-deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse-deterrent technology to reduce the abuse and misuse of fentanyl patches. It is also exploring transdermal delivery of proteins and peptides such as exenatide for type 2 diabetes and follicle-stimulating hormone (FSH) for infertility.